wamj-transwhitelogo.png
  • Interview

    • Cover Story
    • Entrepreneur
  • Reports

    • Biopharma
    • Special Report
  • News & Events

    • Conference
    • Latest News
  • Publication

  • About Us

    • About WAMJ
    • Editorial Board
    • Editorial Letter
    • Sponsorship
  • More

    Use tab to navigate through the menu items.
    • All
    • Cover Story
    • Entrepreneur
    • Biopharmaceutical reports
    • Special Reports
    • Letter
    • Conference
    • Latest Issue
    • biopharma r1
    • biopharma r2
    • biopharma r3
    • special r1
    • cover r1
    • letter r1
    • latest r1
    • con r1
    • cover r2
    Search
    Politicizing Science

    Politicizing Science

    Biopharmaceutical Report I Issue12_December 2016 POLITICIZING SCIENCE BY STEVE USDIN, WASHINGTON EDITOR While the FDA reform provisions...
    NY-ESO-1 therapy renewed enthusiasm underscored by new checkpoint inhibitors

    NY-ESO-1 therapy renewed enthusiasm underscored by new checkpoint inhibitors

    Biopharmaceutical Report III Issue11_September 2016 NY-ESO-1 targeting immunotherapies are seeing renewed clinical development interest...
    Democratizing Antibodies

    Democratizing Antibodies

    Biopharmaceutical Report II Issue11_September 2016 “Will it be mammalian cells forever? Or is there an opportunity to get even better and...
    FDA Review Policies for PD-1/PD-L1 Inhibitors Spark Expert Debate

    FDA Review Policies for PD-1/PD-L1 Inhibitors Spark Expert Debate

    Biopharmaceutical Report I Issue11_September 2016 The potential for changes to FDA oncology drug application review and approval policies...
    PCSK9 Inhibitor Competition: Amgen, Scanofi, and Regeneron Show Equally Decent CVOT Outlooks

    PCSK9 Inhibitor Competition: Amgen, Scanofi, and Regeneron Show Equally Decent CVOT Outlooks

    Biopharmaceutical Report II Issue10_July 2016 • Comparable CV effect expected across PCSK9 inhibitor class • Post-hoc MACE results in...
    South Korea Trials Drive Further Opportunities for Global Pharma and CROs

    South Korea Trials Drive Further Opportunities for Global Pharma and CROs

    Biopharmaceutical Report I Issue10_July 2016 • Goals to improve regulation and site standards • Korean data used in Japanese...
    Changing the Channel

    Changing the Channel

    Overcoming Crisis : Reproducibility Initiatives Biopharmaceutical Report III Issue9_April 2016 --Strategy-- CHANGING THE CHANNEL By Mark...
    Early CAR-T multiple myeloma data promising, though efficacy, safety remain unclear

    Early CAR-T multiple myeloma data promising, though efficacy, safety remain unclear

    Biopharmaceutical Report II Issue9_April 2016 • Source of anti-CD19 CAR-Ts’ benefit obscure • Targeting multiple antigens may be...
    Samsung RA biosimilar EU uptake tied to perceived cost despite physician concerns

    Samsung RA biosimilar EU uptake tied to perceived cost despite physician concerns

    Biopharmaceutical Report I Issue9_April 2016 • Reference companies may lower drug prices too • Payers may mandate biosimilar use in...
    Controlling Drug Prices

    Controlling Drug Prices

    Biopharmaceutical Report III Issue8_Novemver 2015 Goodwill Hunting Martin Shkreli and Hillary Clinton last week provided the flint and...
    1/2
    • Grey Facebook Icon
    • Grey Twitter Icon
    • Grey LinkedIn Icon

    Subscribe to Our Journal

    Thanks for submitting!

    Email: wgroup@wmedical.org
    Tel: 201-402-1400